Literature DB >> 17006970

Discounting in economic evaluations: stepping forward towards optimal decision rules.

Hugh Gravelle1, Werner Brouwer, Louis Niessen, Maarten Postma, Frans Rutten.   

Abstract

The National Institute for Clinical Excellence has recently changed its guidelines on discounting costs and effects in economic evaluations. In common with most other regulatory bodies it now requires that health effects should be discounted at the same rate as costs. We show that the guideline leads to sub-optimal decisions because it fails to account for the changing value of health. NICE (and other regulatory bodies) should either use differential discounting or stipulate how the changing value of health should otherwise be dealt with. We also show how binding health service budget constraints should be incorporated in evaluations. Copyright (c) 2006 John Wiley & Sons, Ltd.

Mesh:

Year:  2007        PMID: 17006970     DOI: 10.1002/hec.1168

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  30 in total

1.  Points to consider in assessing and appraising predictive genetic tests.

Authors:  Wolf H Rogowski; Scott D Grosse; Jürgen John; Helena Kääriäinen; Alastair Kent; Ulf Kristofferson; Jörg Schmidtke
Journal:  J Community Genet       Date:  2010-10-16

2.  Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.

Authors:  Mareike Schad; Jürgen John
Journal:  Eur J Health Econ       Date:  2010-12-19

3.  Exploring a new method for deriving the monetary value of a QALY.

Authors:  Carl Tilling; Marieke Krol; Arthur E Attema; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2015-08-20

4.  The new myth: the social value of the QALY.

Authors:  Werner Brouwer; Job van Exel; Rachel Baker; Cam Donaldson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  The value of a QALY: individual willingness to pay for health gains under risk.

Authors:  Ana Bobinac; Job van Exel; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

6.  Are some QALYs more equal than others?

Authors:  E J van de Wetering; N J A van Exel; J M Rose; R J Hoefman; W B F Brouwer
Journal:  Eur J Health Econ       Date:  2014-12-06

7.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

8.  Differential time preferences for money and quality of life.

Authors:  M B Y Parouty; H H Le; D Krooshof; M J Postma
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

9.  Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach.

Authors:  Stefan A Baeten; N Job A van Exel; Maaike Dirks; Marc A Koopmanschap; Diederik Wj Dippel; Louis W Niessen
Journal:  Cost Eff Resour Alloc       Date:  2010-11-17

10.  Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study.

Authors: 
Journal:  BMJ       Date:  2009-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.